B Guy

Summary

Affiliation: Sanofi Pasteur

Publications

  1. ncbi From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
    Bruno Guy
    Research and Development, Sanofi Pasteur, 69280 Marcy l Etoile, France
    Vaccine 29:7229-41. 2011
  2. ncbi Strategies to improve the effect of vaccination in the elderly: the vaccine producer's perspective
    B Guy
    Sanofi Pasteur, 69280 Marcy l Etoile, France
    J Comp Pathol 142:S133-7. 2010
  3. ncbi Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses
    Bruno Guy
    Sanofi Pasteur, Research and Development, 1541 Av Marcel Merieux, 69280 Marcy l Etoile, France
    Vaccine 28:632-49. 2010
  4. ncbi Immunogenicity of sanofi pasteur tetravalent dengue vaccine
    Bruno Guy
    Research Department, Sanofi Pasteur, Marcy l Etoile, France
    J Clin Virol 46:S16-9. 2009
  5. ncbi Evaluation of interferences between dengue vaccine serotypes in a monkey model
    Bruno Guy
    Research and Discovery Departments, Sanofi Pasteur, Marcy l Etoile, France
    Am J Trop Med Hyg 80:302-11. 2009
  6. ncbi Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects
    Bruno Guy
    Research Department, Sanofi Pasteur, Marcy l Etoile, France
    Vaccine 26:5712-21. 2008
  7. ncbi The perfect mix: recent progress in adjuvant research
    Bruno Guy
    Research Department, Sanofi Pasteur, Campus Merieux, 69280 Marcy l Etoile, France
    Nat Rev Microbiol 5:505-17. 2007
  8. ncbi Effects of the nature of adjuvant and site of parenteral immunization on the serum and mucosal immune responses induced by a nasal boost with a vaccine alone
    B Guy
    Research Department, Pasteur Merieux Connaught, 69280 Marcy l Etoile, France
    Clin Diagn Lab Immunol 5:732-6. 1998
  9. ncbi Comparison between targeted and untargeted systemic immunizations with adjuvanted urease to cure Helicobacter pylori infection in mice
    B Guy
    Research Department, Pasteur Merieux Connaught, Marcy l Etoile, France
    Vaccine 17:1130-5. 1999
  10. ncbi Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)
    Violette Sanchez
    Sanofi Pasteur, Research and Development Department, Marcy l'Etoile, France
    Vaccine 24:4914-26. 2006

Collaborators

Detail Information

Publications23

  1. ncbi From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
    Bruno Guy
    Research and Development, Sanofi Pasteur, 69280 Marcy l Etoile, France
    Vaccine 29:7229-41. 2011
    ..Here we discuss the different steps and challenges of developing CYD TDV, from research to industrialization, and summarize some of the challenges to the successful introduction of a dengue vaccine into immunization programs...
  2. ncbi Strategies to improve the effect of vaccination in the elderly: the vaccine producer's perspective
    B Guy
    Sanofi Pasteur, 69280 Marcy l Etoile, France
    J Comp Pathol 142:S133-7. 2010
    ..These different possibilities, alone or in combination, could improve vaccine efficacy in elderly human populations...
  3. ncbi Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses
    Bruno Guy
    Sanofi Pasteur, Research and Development, 1541 Av Marcel Merieux, 69280 Marcy l Etoile, France
    Vaccine 28:632-49. 2010
    ....
  4. ncbi Immunogenicity of sanofi pasteur tetravalent dengue vaccine
    Bruno Guy
    Research Department, Sanofi Pasteur, Marcy l Etoile, France
    J Clin Virol 46:S16-9. 2009
    ..Clinical and pre-clinical results support the favourable immunogenicity and short-term safety of the dengue TV. Future studies will establish the longevity of the vaccine-induced immunity and requirements for boosters...
  5. ncbi Evaluation of interferences between dengue vaccine serotypes in a monkey model
    Bruno Guy
    Research and Discovery Departments, Sanofi Pasteur, Marcy l Etoile, France
    Am J Trop Med Hyg 80:302-11. 2009
    ..The applicability of these data to human responses is discussed...
  6. ncbi Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects
    Bruno Guy
    Research Department, Sanofi Pasteur, Marcy l Etoile, France
    Vaccine 26:5712-21. 2008
    ..These data are consistent with the previously demonstrated excellent safety of these dengue vaccines in flavivirus-naive and primed individuals...
  7. ncbi The perfect mix: recent progress in adjuvant research
    Bruno Guy
    Research Department, Sanofi Pasteur, Campus Merieux, 69280 Marcy l Etoile, France
    Nat Rev Microbiol 5:505-17. 2007
    ....
  8. ncbi Effects of the nature of adjuvant and site of parenteral immunization on the serum and mucosal immune responses induced by a nasal boost with a vaccine alone
    B Guy
    Research Department, Pasteur Merieux Connaught, 69280 Marcy l Etoile, France
    Clin Diagn Lab Immunol 5:732-6. 1998
    ..Some of these sites may represent crossroads between systemic and mucosal immunity...
  9. ncbi Comparison between targeted and untargeted systemic immunizations with adjuvanted urease to cure Helicobacter pylori infection in mice
    B Guy
    Research Department, Pasteur Merieux Connaught, Marcy l Etoile, France
    Vaccine 17:1130-5. 1999
    ..Systemic immunization with appropriate schedules and formulations could constitute a valuable approach to cure Helicobacter pylori infection...
  10. ncbi Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)
    Violette Sanchez
    Sanofi Pasteur, Research and Development Department, Marcy l'Etoile, France
    Vaccine 24:4914-26. 2006
    ..Lessons learned from these results will help us to pursue the development of safe and immunogenic vaccines...
  11. ncbi New adjuvants for parenteral and mucosal vaccines
    Bruno Guy
    Research Department, Aventis Pasteur, Marcy l Etoile, France
    Therapie 60:235-41. 2005
    ..As our knowledge of the cell types and cytokines interacting in the immune responses increases, so does our understanding of the mode of action of adjuvants, as well as the way in which they produce adverse effects...
  12. ncbi Comparison by flow cytometry of immune changes induced in human monocyte-derived dendritic cells upon infection with dengue 2 live-attenuated vaccine or 16681 parental strain
    Violette Sanchez
    Research Department, Sanofi Pasteur, Campus Merieux, 69280 Marcy l'Etoile, France
    FEMS Immunol Med Microbiol 46:113-23. 2006
    ..In conclusion, these in vitro experiments using primary human dendritic cells may participate, in combination with other assays, to the evaluation of the immunogenicity and safety of dengue vaccine candidates...
  13. ncbi Immunological foundations to the quest for new vaccine adjuvants
    Nicolas Burdin
    Aventis Pasteur, Research and Development, , Marcy l'Etoile, France
    BioDrugs 18:79-93. 2004
    ..Used alone or in combination, such synthetic adjuvants will allow stimulation or modulation in a safe and efficient manner of strong effector, regulatory and memory immune mechanisms...
  14. ncbi Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4
    Florence Deauvieau
    Research Department, Sanofi Pasteur, Marcy l Etoile, France
    Am J Trop Med Hyg 76:144-54. 2007
    ....
  15. ncbi Towards a dengue vaccine: progress to date and remaining challenges
    Bruno Guy
    Sanofi Pasteur, 1541 Avenue Marcel Merieux, 69280 Marcy l Etoile, France
    Comp Immunol Microbiol Infect Dis 31:239-52. 2008
    ..This review presents the current state of knowledge and discusses the challenges of further clinical development...
  16. ncbi Do Th1 or Th2 sequence motifs exist in proteins? Identification of amphipatic immunomodulatory domains in Helicobacter pylori catalase
    Bruno Guy
    Research Department, Aventis Pasteur, Campus Merieux, 69280 Marcy l Etoile, France
    Immunol Lett 96:261-75. 2005
    ..Our data suggest that Th1 and/or Th2 motifs may generally exist on proteins, thus offering the possibility of a rational modulation of the immune response...
  17. ncbi Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones
    V Sanchez
    Aventis Pasteur, , Research Department, Marcy l'Etoile, France
    FEMS Immunol Med Microbiol 30:157-65. 2001
    ..Moreover, the results obtained in protection against H. pylori with such formulations should lead the way to future clinical trials...
  18. ncbi Comparison of polymorphonuclear cells from healthy donors and differentiated HL-60 cells as phagocytes in an opsonophagocytic assay using antigen-coated fluorescent beads
    B Guy
    Research Department, Aventis Pasteur, Campus Merieux, 69280 Marcy l Etoile, France
    Clin Diagn Lab Immunol 7:314-7. 2000
    ..Nevertheless, differentiated HL-60 cells could be a convenient and standardized source of cells to evaluate the functionality of specific antibodies to vaccine candidates as a coating on fluorescent beads...
  19. ncbi Depletion of human NK and CD8 cells prior to in vitro H1N1 flu vaccine stimulation increases the number of gamma interferon-secreting cells compared to the initial undepleted population in an ELISPOT assay
    Christophe Dercamp
    Research Department, Aventis Pasteur, 69280 Marcy l'Etoile, France
    Clin Diagn Lab Immunol 9:230-5. 2002
    ..Such cross-regulations occur even in vitro during the antigenic stimulation step...
  20. ncbi Memory B and T cell responses induced by serotype 4 Streptococcus pneumoniae vaccines: longitudinal analysis comparing responses elicited by free polysaccharide, conjugate and carrier
    Florence Deauvieau
    Sanofi Pasteur, Discovery Department, 69280 Marcy l Etoile, France
    Vaccine 28:576-82. 2009
    ..These data indicate that the nature and long-term kinetics of the anti-PS4 antibody response induced by the conjugate vaccine are similar to "classical" T-dependent response elicited by conventional protein antigens...
  21. ncbi Evaluation of events occurring at mucosal surfaces: techniques used to collect and analyze mucosal secretions and cells
    Bruno Guy
    Research Department, Aventis Pasteur, Campus Merieux, 69280 Marcy l'Etoile, France
    Clin Diagn Lab Immunol 9:753-62. 2002
  22. ncbi Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice
    Jean Francois Nicolas
    University Lyon 1, UFR Lyon Sud, IFR 128 Biosciences Lyon Gerland, Institut National de la Santé et de la Recherche Médicale U503, 21 Avenue Tony Garnier, Lyon Cedex 07, Lyon 69365, France
    Expert Rev Vaccines 7:1201-14. 2008
    ....
  23. ncbi Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori
    Stavros Sougioultzis
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Vaccine 21:194-201. 2002
    ..In conclusion, rectal delivery of 5 microg LT is safe and induces vigorous systemic anti-LT immune responses. Further studies are needed to determine if LT can be an effective adjuvant for rectally delivered antigens...